Nodal peripheral T-cell lymphoma: a prognostic index developed by the T-cell project
Year: 2026
Type: article
Study design: Observational Study
Abstract: To characterize real-world treatment patterns and outcomes in nodal peripheral T-cell lymphoma (PTCL) and to develop and externally validate a contemporary clinical prognostic model, we analyzed patients prospectively registered in the International T-Cell Project 2 (TCP2). Between January 2018 and January 2026, 1,465 patients with PTCL were registered; 959 with nodal PTCL by the 2016 WHO classification (PTCL not otherwise specified (PTCL-NOS), systemic anaplastic large-cell lymphoma (ALCL; ALK-positive or ALK-negative), and T-follicular helper lymphoma (TFHL)) were analyzed. The primary endpoint was 2-year progression-free survival (PFS); the model was externally validated in the TCP1 cohort (n = 1,016). The cohort comprised 396 PTCL-NOS (41%), 263 TFHL (27%), 211 ALK-negative ALCL (22%), and 89 ALK-positive ALCL (9%). First-line therapy was CHOEP in 340 (37%), CHOP in 260 (29%), and brentuximab vedotin-CHP in 139 (15%); 156 underwent consolidative stem cell transplantation. After a median follow-up of 25.3 months, 2-year PFS and overall survival were 35.3% and 54.3%, respectively. In multivariate analysis, diagnosis other than ALCL, age ≥65 years, ECOG performance status ≥2, thrombocytopenia, extranodal involvement, and elevated LDH were independently associated with inferior PFS. A six-variable score using these factors stratified patients into 3 risk groups - low (score 0-1), intermediate (2-3), and high (4-6) with 2-year PFS, 65%, 33%, and 16% respectively (P < .001) and was confirmed in the TCP1 validation cohort. Outcomes for nodal PTCL remain poor with current therapy; the externally validated TCP score offers a contemporary, complementary tool for risk stratification and identification of patients at high risk of treatment failure. ClinicalTrials.gov NCT03964480, NCT01142674.
Source: Blood Advances
Authors: Stefano Luminari, Nazarii Shokun, Luana Conte, Kateryna Filonenko, Giorgio De Nunzio, Carlos Sergio Chiattone, Henry Miles Prince, Camila Peña, Raimundo Gazitúa, Ciprian Tomuleasa, Yasodha Natkunam, Iryna Kryachok, Ilias Stagakis, Tetiana Skrypets, Neeraj Arora, Won Seog Kim, Eliza Chung, Sabina Ioana Doinita Iluta, Cameron Wellard, Carolina V Mahuad, Lorena Fiad, Fernando Warley, Graciela Alfonso, Silvia Gambara, Thais Fischer, Iryna Tytorenko, Danielle Leão Cordeiro de De Farias, Eliza A Hawkes, Ranjana H Advani, Francine M Foss, Julie M. Vose, Massimo Federico
Institutions: University of Modena and Reggio Emilia, University of Salento, Faculdade de Ciências Médicas da Santa Casa de São Paulo, The University of Melbourne, Peter MacCallum Cancer Centre, Hospital del Salvador, Fundación Arturo López Pérez, Iuliu Hațieganu University of Medicine and Pharmacy, Stanford University, National Cancer Institute, Kantonsspital St. Gallen, Tata Medical Center, Samsung Medical Center, Sungkyunkwan University, Monash University, Hospital Alemán, Hospital Italiano La Plata, Universidad Hospital Italiano, Hospital Posadas, AC Camargo Hospital, Beneficência Portuguesa de São Paulo, Yale University, University of Nebraska Medical Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,800
OpenAlex ID: W7235911374
